[1] Santoiemma PP, Powell DJ Jr.Tumor infiltrating lymphocytes in ovarian cancer[J]. Cancer Biol Ther,2015,16(6):807-820.
[2] Hou JJ, Hu ShY, Liu TT.The clinical value of serum tumor markers in the early diagnosis of ovarian cancer [J].Chinese Journal of Immunology, 2014, 30 (8): 1101-1104. (in Chinese)
侯娟娟, 虎淑妍, 刘婷婷,等. 血清肿瘤标志物在卵巢癌早期诊断中的临床价值[J]. 中国免疫学杂志, 2014, 30(8):1101-1104.
[3] Sun J.Detective significance of CA19-9, CA125 and HE4 in ovarian cancer[J].Chinese Journal of Laboratory Diagnosis,2016,20(7):1146-1147. (in Chinese)
孙洁.CA19-9、CA125及HE4在卵巢癌中的检测意义[J].中国实验诊断学,2016,20(7):1146-1147.
[4] Sun J, Yang SF, Bai TM, et al. Study on the content and inhibitory function of CD4+ CD25+ regulatory T cells in ascites and peripheral blood of patients with ovarian cancer[J].Chinese Journal of Human Sexuality,2016,25(2):17-19. (in Chinese)
孙洁,杨素芬,白图门,等.卵巢癌患者腹水及外周血CD4+ CD25+调节性T细胞含量及抑制功能的研究[J].中国性科学,2016,25(2):17-19.
[5] Yang Y. Expression and clinical significance of CD4+ CD25+ Foxp3+ regulatory T cells in patients with esophageal cancer[D]. Zhengzhou University, 2010. (in Chinese)
杨轶. 食管癌患者CD4+ CD25+ Foxp3+调节性T细胞的表达及其临床意义[D]. 郑州大学, 2010.
[6] Liu J, Matulonis UA.New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances[J].Clin Cancer Res,2014, 20(20):5150-5156.
[7] Gao CH, Gao QSh, Peng LH. Study of dynamic changes of peripheral blood D-dimer,IL-6 and Fibrinogen of patients with ovarian cancer[J].Chinese Journal of Immunology, 2015,31(4):534-536. (in Chinese)
高翠红,高庆双,彭利红.卵巢癌患者外周血D-二聚体、FIB水平与IL-6动态变化的研究[J].中国免疫学杂志,2015,31(4):534-536.
[8] Mao L. Analysis on CD4+ CD25+ Treg/CD4+T cells contents and significance in ascites and peripheral blood of ovarian cancer patients[J].Maternal and Child Health Care of China,2016,31(22):4871-4874. (in Chinese)
毛柳.卵巢癌腹水及外周血CD4+ CD25+ Treg/CD4+T细胞含量及其意义分析[J].中国妇幼保健,2016,31(22):4871-4874.
[9] Qiao XY, Niu RG, Wei ShQ. Changes of CD4+ CD25+ regulatory T cells in patients with advanced lung cancer before and after chemotherapy and their effects[J].Chinese Remedies and Clinics,2015,15(5):680-682. (in Chinese)
乔晓媛,牛润桂,魏淑青.中晚期肺癌患者化疗前后的CD4+ CD25+调节性T细胞含量变化及其作用研究[J].中国药物与临床,2015,15(5):680-682.
[10] Shen W,Tian G.Changes of CD4+ CD25+ Treg cells, TGF-beta 1 and IL-10 in epithelial ovarian cancer[J].Chinese Journal of Gerontology, 2011, 31(24):4776-4778. (in Chinese)
沈玮, 田庚. CD4+ CD25+ Treg细胞、TGF-β1和IL-10在上皮性卵巢癌中的变化[J]. 中国老年学杂志, 2011, 31(24):4776-4778.
[11] Wang YF,Guo Y,Wang HL,et al.The clinical value of HE4, CA125 and ROMA in the differential diagnosis of benign and malignant ovarian tumors[J].Labeled Immunoassays and Clinical Medicine,2017,24(11):1216-1220, 1279. (in Chinese)
王雅菲,郭玉,王慧利,等.HE4、CA125及ROMA在卵巢肿瘤良恶性鉴别的临床应用价值[J].标记免疫分析与临床,2017,24(11):1216-1220, 1279.
[12] Wang F. The value of serum HE4 combined with CA125 and CA19-9 in the diagnosis of ovarian cancer [D]. Zhengzhou University, 2010. (in Chinese)
王锋.血清HE4联合CA125、CA19-9检测在卵巢癌诊断中的价值[D].郑州大学,2010.
[13] Xiao WH. Clinical significance of detection of HE4 combined with CA72-4 and CA19-9 serum saccharide antigens in patients with ovarian cancer[J]. Journal of Clinical Hematology,2016,29(5):808-810. (in Chinese)
肖伟欢.HE4联合CA72-4、CA19-9血清糖类抗原检测对卵巢癌患者的临床意义[J].临床血液学杂志,2016,29(5):808-810.
[14] Liu YX, Shou HCh. The value of combined detection of CA199 and CA125 in the differential diagnosis and judgment of ovarian masses [J].Maternal and Child Health Care of China,2018,33(1): 64-66. (in Chinese)
刘永霞,寿好长.CA199、CA125联合检测在卵巢肿块鉴别及病情判断中的价值[J].中国妇幼保健,2018,33(1):64-66.
|